Lundbeckfond Ventures, the venture capital fund owned by Denmark-based pharmaceutical company Lundbeck, and VC firm 5AM Ventures have co-led a $16m series A round for US-based biopharmaceutical company scPharmaceuticals.
scPharmaceuticals creates innovative and important new therapeutic options that make time-released drug administration easy and convenient enough for both clinical situations and self-application without the need for intravenous needles.
The funds will allow the company to continue building a pipeline behind its two lead programs: a cephalosporin antibiotic and a drug-device combination based around furosemide, which is administered in case of a heart failure, Both treatments currently require intravenous injections.
Neither of scPharmaceuticals’s programs is currently available. The company expects to launch both products in 2016.